Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net IncomeGlobeNewsWire • Wednesday
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)GlobeNewsWire • 10/25/26
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026GlobeNewsWire • 10/21/26
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026GlobeNewsWire • 08/31/26
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent PatientsGlobeNewsWire • 08/28/26
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026GlobeNewsWire • 08/24/26
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market PresenceGlobeNewsWire • 07/29/26
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026GlobeNewsWire • 07/15/26
Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' NowZacks Investment Research • 07/10/26
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment LandscapeGlobeNewsWire • 06/30/26
New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with HypertriglyceridemiaGlobeNewsWire • 05/27/26
All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong BuyZacks Investment Research • 05/05/26